StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Investment analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $0.55 on Wednesday. The stock has a 50 day moving average price of $0.55 and a 200 day moving average price of $0.73. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $9.24. The stock has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. World Investment Advisors LLC acquired a new stake in shares of Marinus Pharmaceuticals in the third quarter valued at approximately $104,000. Virtu Financial LLC purchased a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at about $54,000. JPMorgan Chase & Co. grew its holdings in shares of Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares during the period. Finally, Deltec Asset Management LLC acquired a new stake in Marinus Pharmaceuticals during the fourth quarter worth about $107,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.